Literature DB >> 11408384

Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR: interaction with angiotensin type 2 receptors.

J Varagic1, D Susic, E D Frohlich.   

Abstract

This study was designed to determine the effects of angiotensin II type 1 (AT(1)) receptor inhibition on coronary hemodynamics and ventricular mass and hydroxyproline content and the additive effects of angiotensin II type 2 (AT(2)) receptor inhibition in spontaneously hypertensive rats (SHR). The selective AT(1) receptor antagonist candesartan (10 mg/kg per day) was administered alone or in combination with the AT(2) receptor antagonist PD 123319 (50 mg/kg per day) for 12 weeks. Control SHR received placebo for the same period. Left and right ventricular coronary blood flow, blood flow reserve, and minimal coronary vascular resistance were determined by using radiomicrospheres in male 35-week-old rats. Mean arterial pressure; total peripheral resistance; left and right ventricular, renal, and aortic weights; and hydroxyproline concentration were also determined. Candesartan reduced mean arterial pressure and left ventricular, renal, and aortic masses, as well as hydroxyproline concentration and minimal coronary vascular resistance of both ventricles. PD 123319 partially prevented the hypotensive effect of AT(1) receptor inhibition and reversed the effect on myocardial hydroxyproline concentration. These data suggest that AT(2) receptors contribute to the hypotensive and antifibrotic effects but not the coronary hemodynamic improvement or reduced left ventricular mass of AT(1) receptor inhibition in these adult SHR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408384     DOI: 10.1161/01.hyp.37.6.1399

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

Review 1.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

2.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2002

3.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2001-10

4.  Hypertension research program at ochsner: a program in translational research.

Authors:  Edward Frohlich
Journal:  Ochsner J       Date:  2002

5.  An updated concept for left ventricular hypertrophy risk in hypertension.

Authors:  Edward D Frohlich
Journal:  Ochsner J       Date:  2009

Review 6.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 7.  Vascular angiotensin II actions mediated by angiotensin II type 2 receptors.

Authors:  Ruth E Hannan; Robert E Widdop
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

8.  Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials.

Authors:  Songtao Liu; Jing Han; Marcelo S Nacif; Jacquin Jones; Nadine Kawel; Peter Kellman; Christopher T Sibley; David A Bluemke
Journal:  J Cardiovasc Magn Reson       Date:  2012-12-28       Impact factor: 5.364

9.  Influence of Angiotensin II Subtype 2 Receptor (AT(2)R) Antagonist, PD123319, on Cardiovascular Remodelling of Aged Spontaneously Hypertensive Rats during Chronic Angiotensin II Subtype 1 Receptor (AT(1)R) Blockade.

Authors:  Emma S Jones; M Jane Black; Robert E Widdop
Journal:  Int J Hypertens       Date:  2012-03-04       Impact factor: 2.420

Review 10.  LOX-1 and angiotensin receptors, and their interplay.

Authors:  Xianwei Wang; M Ian Phillips; Jawahar L Mehta
Journal:  Cardiovasc Drugs Ther       Date:  2011-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.